A Cross‐Sectional Study of Extended‐Spectrum β ‐Lactamase–Producing Escherichia coli Isolated From Clinical Samples: Single‐Center Investigation in Indonesia
Authors:
- Fitrotin AzizahFAFitrotin Azizah
- Dita ArtantiDADita Artanti
- Yety Eka Sispita SariYSYety Eka Sispita Sari
- Anindita Riesti Retno ArimurtiAAAnindita Riesti Retno Arimurti
- Arya IswaraAIArya Iswara
- Afifah KhairunnisaAKAfifah Khairunnisa
- Muhammad Evy PrastiyantoMPMuhammad Evy Prastiyanto
- Daniel GeletaDGDaniel Geleta
Open Access
- 1 January 2025
- journal article
- Published by Wiley in International Journal of Microbiology
- Vol. 2025 (1) , 3743202
Abstract
The emergence of extended‐spectrum beta‐lactamase–producing Escherichia coli (ESBL‐producing E. coli ) is a significant public health concern, particularly in developing countries like Indonesia, where reports on the prevalence and characteristics of these resistant strains are scarce. This lack of data hampers effective infection control and antibiotic stewardship efforts. This study is aimed at investigating the prevalence and assessing the antimicrobial susceptibility profiles of ESBL‐producing E. coli isolated from clinical samples of Indonesian patients, thereby contributing to an understanding of antibiotic resistance patterns in this region. A cross‐sectional study was conducted at RSUD dr. Adhyatma Hospital, Semarang, Indonesia, over 3 years (from January 2022 to December 2024). Clinical specimens were obtained from patients diagnosed with E. coli infections, and isolates were identified and assessed for antibiotic susceptibility utilizing the VITEK2 Compact system. Data were examined via the Fisher’s exact test. Out of 449 E. coli isolates, 199 (44.3%) were identified as ESBL, with the highest prevalence in pus (35.6%) and urine (27.2%). ESBL‐producing E. coli isolates demonstrated high sensitivity (above 90%) to amoxicillin–clavulanic acid, ceftazidime, ertapenem, meropenem, and tigecycline. Our study also underlined the higher prevalence of multidrug resistance (MDR) in ESBL compared to non‐ESBL. The results highlight the urgent need for enhanced surveillance and infection control measures in healthcare settings to combat the spread of ESBL‐producing E. coli . Healthcare professionals, including nurses and clinicians, must be aware of this resistance pattern to guide empirical treatment choices and improve patient outcomes in managing infections caused by these resistant strains.Keywords
This publication has 30 references indexed in Scilit:
- Prevalence and antimicrobial resistance profiles of multidrug-resistant bacterial isolates from urinary tract infections in Indonesian patients: A cross-sectional studyClinical Infection in Practice, 2024
- Prevalence of extended spectrum beta-lactamase (ESBL) Escherichia coli recovered from ICU and non-ICU at dr. Zainoel Abidin General HospitalBIO Web of Conferences, 2024
- MDR/XDR/PDR or DTR? Which definition best fits the resistance profile of Pseudomonas aeruginosa?Current Opinion in Infectious Diseases, 2023
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysisThe Lancet, 2022
- β-Lactamases and β-Lactamase Inhibitors in the 21st CenturyJournal of Molecular Biology, 2019
- Prevalence of Multidrug Resistance and Extended-Spectrum β-Lactamase Carriage of Clinical Uropathogenic Escherichia coli Isolates in Riyadh, Saudi ArabiaInternational Journal of Microbiology, 2018
- Characteristics of Extended-Spectrum β-Lactamase–Producing Escherichia coli in Retail Meats and Shrimp at a Local Market in VietnamFoodborne Pathogens and Disease, 2015
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistanceClinical Microbiology and Infection, 2012
- Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapyInfection, 2011
- Molecular characterization of extended-spectrum β-lactamases in clinical Escherichia coli and Klebsiella pneumoniae isolates from Surabaya, IndonesiaJournal of Antimicrobial Chemotherapy, 2010